Author

Bożena Kukiełka-Budny

Observed names: B Kukiełka-Budny, B.D. Kukielka-Budny, Bozena Budny, Bozena Kukielka-Budny, Bożena Budny, Bożena Kukielka-Budny, Bożena Kukiełka‑Budny

Institution: Lublin Oncology Center

Observed institutions: University of California, Los Angeles, National Taiwan University, Friedrich-Alexander-Universität Erlangen-Nürnberg, Lublin Oncology Center, National Taiwan University Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Moscow City Oncology Hospital №62, Government of the Republic of Tatarstan

ORCID: 0000-0002-2837-5870

Observed ORCID: 0000-0002-2837-5870

OpenAlex ID: A5045835088

Ribociclib plus Endocrine Therapy in Early Breast Cancer

2024 · Dennis Slamon, Oleg Lipatov, et al. · New England Journal of Medicine · 476

Primary and secondary prevention of breast cancer

2017 · Agnieszka Kolak, Marzena Kamińska, et al. · Annals of Agricultural and Environmental Medicine · 397

PDF

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial

2022 · Nicholas J. Vogelzang, Tomasz M. Beer, et al. · JAMA Oncology · 105

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

2021 · Lori J. Goldstein, Mauro Mansutti, et al. · Breast Cancer Research and Treatment · 104

PDF

[Epidemiology and risk factors of hepatocellular carcinoma].

2017 · Agnieszka Budny, Piotr Kozłowski, et al. · PubMed · 79

Life quality of women with breast cancer after mastectomy or breast conserving therapy treated with adjuvant chemotherapy

2015 · Marzena Kamińska, Tomasz Ciszewski, et al. · Annals of Agricultural and Environmental Medicine · 48

PDF

Obesity as a tumour development triggering factor

2019 · Agnieszka Budny, Cezary Grochowski, et al. · Annals of Agricultural and Environmental Medicine · 39

PDF

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

2021 · Karen A. Gelmon, Peter A. Fasching, et al. · European Journal of Cancer · 37

PDF

[Epidemiology and diagnosis of breast cancer].

2019 · Agnieszka Budny, Elżbieta Starosławska, et al. · PubMed · 32

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

2023 · Judith Balmaña, Peter A. Fasching, et al. · Breast Cancer Research and Treatment · 27

Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

2024 · Kohei Shitara, Eric Van Cutsem, et al. · Journal of Clinical Oncology · 18

PDF

Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B‑cell non‑Hodgkin's lymphoma

2017 · Iwona Hus, Agnieszka Bojarska‑Junak, et al. · Oncology Letters · 18

2025 · Peter A. Fasching, Dennis Slamon, et al. · Clinical Cancer Research · 16

Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

2019 · Matti Aapro, Manuel Ruiz-Borrego, et al. · The Breast · 15

VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2- early breast cancer (EBC)

2023 · P.A. Fasching, D. Slamon, et al. · Annals of Oncology · 7

PDF

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

2024 · Gilles Freyer, Noelia Martinez-Jañez, et al. · The Breast · 6

PDF

Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.

2018 · Ulrich Keilholz, Andrzej Kawecki, et al. · Journal of Clinical Oncology · 4

Principles of induction chemotherapy for non-small cell lung cancer

2001 · St Jabłonka, F Furmanik, et al. · Lung Cancer · 4

Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC).

2026 · Stephen K.L. Chia, Peter A. Fasching, et al. · Journal of Clinical Oncology · 2

PDF

2026 · P.A. Fasching, D.J. Slamon, et al. · ESMO Open

Supplementary Data 1 from Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

2025 · Peter A. Fasching, Dennis Slamon, et al.

Data from Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

2025 · Peter A. Fasching, Dennis Slamon, et al.

Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

2024 · Manish A. Shah, Kohei Shitara, et al. · Journal of Clinical Oncology

203P Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer

2021 · M.E. Cazzaniga, N. Martinez Jañez, et al. · Annals of Oncology

Odległe wyniki leczenia skojarzonego z udziałem przedoperacyjnej chemioterapii i resekcji u chorych na miejscowo zaawansowanego niedrobnokomórkowego raka płuca

2008 · Franciszek Furmanik, Krzysztof Paprota, et al. · Pneumonologia i Alergologia Polska

PDF

Works count: 26

Citation count: 1,434

H-index: 14

I10-index: 14